Author(s):
Omar Yahya Alshargi, Samah Mukhlef Alzaid, Zainab ibrahim Albahouth, Ammar Ali Jaber, Bodoor Saud Al-Dosari
Email(s):
omar.alshargi2@gmail.com , smalzaid@moh.gov.sa , ph.zozo@windowslive.com , ammarali20142015@gmail.com , bsaldosari@kau.edu.sa
DOI:
10.52711/0974-360X.2022.00163 
Address:
Omar Yahya Alshargi1*, Samah Mukhlef Alzaid2, Zainab ibrahim Albahouth3, Ammar Ali Jaber4, Bodoor Saud Al-Dosari5
1College of Pharmacy, Riyadh Elm University, Riyadh 11681, Saudi Arabia.
2Clinical Pharmacy Department, Gurayat General Hospital, Gurayat – Husydah - 3407, 77455, Saudi Arabia.
3Clinical Pharmacy Department, Ministry of Health, Asalam, Riyadh, Saudi Arabia.
4Department of Clinical Pharmacy and Pharmacotherapeutics, Dubai Pharmacy College for Girls, Dubai, United Arab Emirates.
5Pharmacy Department, King Abdulaziz University Hospital, Jeddah 21589, Kingdom of Saudi Arabia.
*Corresponding Author
Published In:
Volume - 15,
Issue - 3,
Year - 2022
ABSTRACT:
Background: Pharmacometabonomics is a new approach developed in the delivery of personalized medicine to improve optimal drug efficacy and safety to patients. We summarized the literature regarding the application of pharmacometabonomics in neurology. Methods: We conducted a systematic search of the literature using Medline via PubMed, from the inception of the database to April 2020. Other articles were searched from the manual search of the included articles. Other information was retrieved from Google Scholar. Data from the included articles were reviewed and summarized based on neurological disorder/drug, experiment employed and clinical application. Results: The search of the literature generated 258 articles, of which 10 were included for review based on the selection criteria. The review of the literature demonstrates that pharmacometabonomics has been used in the prediction of drug efficacy, adverse drug events, and metabolisms in neurological toxicity, schizophrenia, multiple sclerosis, major depressive and bipolar disorders. The commonly employed pharmacometabonomics methods were liquid chromatography coupled with electrochemical coulometric, mass spectrometry, nuclear magnetic resonance, and gas chromatography. Conclusion: Earlier evidence has demonstrated that pharmacometabonomics has the potential of improving drug safety in neurology, through the delivery of personalized medicine. Therefore, more studies are needed to explore its clinical applications in other areas of neurology for optimal outcomes.
Cite this article:
Omar Yahya Alshargi, Samah Mukhlef Alzaid, Zainab ibrahim Albahouth, Ammar Ali Jaber, Bodoor Saud Al-Dosari. Clinical Applications of Pharmacometabonomics in Neurology: Current Status, Future Perspectives and Challenges. Research Journal of Pharmacy and Technology. 2022; 15(3):976-0. doi: 10.52711/0974-360X.2022.00163
Cite(Electronic):
Omar Yahya Alshargi, Samah Mukhlef Alzaid, Zainab ibrahim Albahouth, Ammar Ali Jaber, Bodoor Saud Al-Dosari. Clinical Applications of Pharmacometabonomics in Neurology: Current Status, Future Perspectives and Challenges. Research Journal of Pharmacy and Technology. 2022; 15(3):976-0. doi: 10.52711/0974-360X.2022.00163 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-3-6
REFERENCES:
1. Jørgensen, J.T., A challenging drug development process in the era of personalized medicine. Drug Discovery Today. 2011. 16(19-20): p. 891-897.
2. Chavhan, A.B. and D.M. Bhoi, Pharmacovigillance: Drug Safety Monitoring. Asian Journal of Pharmacy and Technology. 2019. 9(1): p. 49-52.
3. Lazarou, J., B.H. Pomeranz, and P.N. Corey, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998. 279(15): p. 1200-1205.
4. Rajput, M.D., Y. Rajput, and L. Rajput, A Review on Adverse Drug Reaction. Asian Journal of Pharmaceutical Research. 2020. 10(3): p. 221-225.
5. Tejas, K. and D. Ganesh, A Review on Orodispersible Tablets: A Novel Approach. Research Journal of Pharmacy and Technology. 2019. 12(8): p. 3993-4001.
6. Pokorska-Bocci, A., et al., 'Personalized medicine': what’s in a name? Personalized Medicine. 2014. 11(2): p. 197-210.
7. Swapnaa, B. and S.V. Kumar, Personalized Medicine-A Novel approach in Cancer Therapy. Research Journal of Pharmacy and Technology. 2017. 10(1): p. 341-345.
8. Radhakrishnan, A., et al., Personalized Nano Delivery Strategy in Treating Uveitis. Research Journal of Pharmacy and Technology. 2019. 12(4): p. 1997-2008.
9. Deepali, G., et al., Pharmacogenomics: An Overview. Research Journal of Pharmacology and Pharmacodynamics. 2009. 1(2): p. 59-65.
10. Clayton, T.A., et al., Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature. 2006. 440(7087): p. 1073-1077.
11. Nicholson, J.K., E. Holmes, and J.C. Lindon, Metabonomic and Metabolomics Techniques and Their Applications in Mammalian Systems. The Handbook of Metabonomics and Metabolomics. 2007: p. 1-34.
12. Everett, J.R., R.L. Loo, and F.S. Pullen, Pharmacometabonomics and personalized medicine. Annals of Clinical Biochemistry. 2013. 50(6): p. 523-545.
13. Wolf, N.I., et al., Severe hypomyelination associated with increased levels of N-acetylaspartylglutamate in CSF. Neurology. 2004. 62(9): p. 1503-1508.
14. Jain, P., et al., Epilepsy: A neurological cramp. Research Journal of Pharmacology and Pharmacodynamics. 2013. 5(1): p. 1-5.
15. Pavithra, C., et al., A Review on Multiple Sclerosis and its Regimens. Research Journal of Pharmacy and Technology. 2020. 13(8): p. 3977-3982.
16. A't Hart, B., et al., 1H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease. Journal of the Neurological Sciences. 2003. 212(1-2): p. 21-30.
17. Pindoria, S. and N. Sinha, Effects of Age on the Quality of Life of Caregivers of Patients with Mental Illness. Research Journal of Humanities and Social Sciences. 2019. 10(2): p. 629-634.
18. Maric, N.P., et al., Improving Current Treatments for Schizophrenia. Drug Dev Res. 2016. 77(7): p. 357-367.
19. Condray, R., et al., 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. International Journal of Neuropsychopharmacology. 2011. 14(6): p. 756-767.
20. Holmes, E., et al., Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Medicine. 2006. 3(8).
21. Chan, M.K., et al., Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients. Molecular Psychiatry. 2011. 16(12): p. 1189-1202.
22. Paris, J., The mistreatment of major depressive disorder. Can J Psychiatry. 2014. 59(3): p. 148-51.
23. Ji, Y., et al., Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics‐informed pharmacogenomics. Clinical Pharmacology & Therapeutics. 2011. 89(1): p. 97-104.
24. Kaddurah-Daouk, R., et al., Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Translational Psychiatry. 2011. 1(7): p. e26-e26.
25. Zhu, H., et al., Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. PLoS One. 2013. 8(7): p. e68283.
26. Chapekar, N.S., S.R. Bavaskar, and F.J. Sayyad, Bipolar Disorder and Role of Lithium in Its Management: An Overview. Research Journal of Pharmacology and Pharmacodynamics. 2010. 2(2): p. 111-116.
27. Lan, M., et al., Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Molecular Psychiatry. 2009. 14(3): p. 269-279.
28. Cunningham, K., et al., Pharmacometabonomic characterization of xenobiotic and endogenous metabolic phenotypes that account for inter-individual variation in isoniazid-induced toxicological response. Journal of Proteome Research. 2012. 11(9): p. 4630-4642.
29. Kinross, J.M., et al., Metabolic phenotyping for monitoring surgical patients. The Lancet. 2011. 377(9780): p. 1817-1819.
30. Hinz, K.-P., et al., Characterization of surgical aerosols by the compact single-particle mass spectrometer LAMPAS 3. Analytical and Bioanalytical Chemistry. 2011. 401(10): p. 3165-3172.
31. Mirnezami, R., et al., Implementation of molecular phenotyping approaches in the personalized surgical patient journey. Annals of Surgery. 2012. 255(5): p. 881-889.
32. Koal, T. and H.-P. Deigner, Challenges in mass spectrometry based targeted metabolomics. Current Molecular Medicine. 2010. 10(2): p. 216-226.
33. Wei, R., Metabolomics and its practical value in pharmaceutical industry. Current Drug Metabolism. 2011. 12(4): p. 345-358.